Literature DB >> 17546828

Screening for urologic malignancies in primary care: pros, cons, and recommendations.

Andrew J Stephenson1, Louis Kuritzky, Steven C Campbell.   

Abstract

Interest in screening for urologic cancers has grown in recent years. This article considers the pros and cons of screening for four epidemiologically compelling urologic cancers: prostate, bladder, kidney, and testicular. Unfortunately, many of the urologic cancers do not meet the criteria for a successful cancer screening program-namely, high prevalence, availability of a sensitive and specific screening test, ability to detect clinically important cancers at an early stage, and cost-effectiveness. While age-based screening for prostate cancer should be offered to the general population after discussion of its benefits and risks, for the other three urologic malignancies the current consensus points more toward selective screening based on specific patient risk factors.

Entities:  

Mesh:

Year:  2007        PMID: 17546828     DOI: 10.3949/ccjm.74.suppl_3.s6

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  4 in total

1.  CKD and risk of renal cell carcinoma: a causal association?

Authors:  Jonathan N Hofmann; Mark P Purdue
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

2.  Bladder tumor in women with microscopic hematuria: an Iranian experience and a review of the literature.

Authors:  Shahin Abbaszadeh; Saeed Taheri; Mohammad Hossein Nourbala
Journal:  Adv Urol       Date:  2009-07-20

Review 3.  Current evidence on screening for renal cancer.

Authors:  Juliet Usher-Smith; Rebecca K Simmons; Sabrina H Rossi; Grant D Stewart
Journal:  Nat Rev Urol       Date:  2020-08-28       Impact factor: 16.430

Review 4.  Epidemiology and screening for renal cancer.

Authors:  Sabrina H Rossi; Tobias Klatte; Juliet Usher-Smith; Grant D Stewart
Journal:  World J Urol       Date:  2018-04-02       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.